作者: Andreia Brandão , Paula Paulo , Manuel R. Teixeira
DOI: 10.3390/IJMS21145036
关键词:
摘要: Prostate cancer (PrCa) ranks among the top five cancers for both incidence and mortality worldwide. A significant proportion of PrCa susceptibility has been attributed to inherited predisposition, with 10–20% cases expected occur in a hereditary/familial context. Advances DNA sequencing technologies have uncovered several moderate- high-penetrance genes, most which previously related known hereditary syndromes, namely breast ovarian (BRCA1, BRCA2, ATM, CHEK2, PALB2) Lynch syndrome (MLH1, MSH2, MSH6, PMS2) genes. Additional candidate genes also suggested, but further evidence is needed include them routine genetic testing. Recommendations based on clinical features, family history, ethnicity established more cost-efficient testing patients families who may be at an increased risk developing PrCa. The identification alterations predisposing help inform screening strategies, as well treatment options, metastatic setting. This review provides overview basis underlying predisposition PrCa, current recommendations, implications management disease.